Phenylethyl Butyrate Enhances the Potency of Second-Line Drugs against Clinical Isolates of Mycobacterium tuberculosis

被引：17

作者：

Grau, Thomas ^{[1
]}

Selchow, Petra ^{[1
]}

Tigges, Marcel ^{[2
,3
]}

Burri, Reto ^{[1
]}

Gitzinger, Marc ^{[2
,3
]}

Boettger, Erik C. ^{[1
,4
]}

Fussenegger, Martin ^{[2
]}

Sander, Peter ^{[1
,4
]}

机构：

[1] Univ Zurich, Inst Med Microbiol, Zurich, Switzerland

[2] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn D BSSE, Basel, Switzerland

[3] BioVersys AG, Basel, Switzerland

[4] Swiss Natl Ctr Mycobacteria, Zurich, Switzerland

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2012年 / 56卷 / 02期

基金：

瑞士国家科学基金会;

关键词：

ETHIONAMIDE; THIACETAZONE; ACTIVATION; MECHANISM; AGENTS;

D O I：

10.1128/AAC.05649-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ethionamide (ETH) is a second-line drug for the treatment of tuberculosis. As a prodrug, ETH has to be activated by EthA. ethA is controlled by its repressor EthR. 2-Phenylethyl-butyrate (2-PEB) inhibits EthR binding, enhances expression of EthA, and thereby enhances the growth-inhibitory effects of ethionamide, isoxyl, and thiacetazone in Mycobacterium tuberculosis strains with resistance to ETH due to inhA promoter mutations but not ethA mutations.

引用

页码：1142 / 1145

页数：4

共 17 条

[1] Thiacetazone, an Antitubercular Drug that Inhibits Cyclopropanation of Cell Wall Mycolic Acids in Mycobacteria
Alahari, Anuradha
Trivelli, Xavier
Guerardel, Yann
Dover, Lynn G.
Besra, Gurdyal S.
Sacchettini, James C.
Reynolds, Robert C.
Coxon, Geoffrey D.
Kremer, Laurent
[J]. PLOS ONE, 2007, 2 (12):
[2] Baulard AR, 2000, J BIOL CHEM, V275, P28326
[3] Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice
Bermudez, LE
Reynolds, R
Kolonoski, P
Aralar, P
Inderlied, CB
Young, LS
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) : 2685 - 2687
[4] Symmetrical and unsymmetrical analogues of isoxyl;: active agents against Mycobacterium tuberculosis
Bhowruth, Veemal
Brown, Alistair K.
Reynolds, Robert C.
Coxon, Geoffrey D.
Mackay, Simon P.
Minnikin, David E.
Besra, Gurdyal S.
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (18) : 4743 - 4747
[5] Molecular Investigation of Resistance to the Antituberculous Drug Ethionamide in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis
Brossier, F.
Veziris, N.
Truffot-Pernot, C.
Jarlier, V.
Sougakoff, W.
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (01) : 355 - 360
[6] Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis
DeBarber, AE
Mdluli, K
Bosman, M
Bekker, LG
Barry, CE
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (17) : 9677 - 9682
[7] HOLLINRAKE K, 1968, British Journal of Diseases of the Chest, V62, P151, DOI 10.1016/S0007-0971(68)80006-3
[8] N-D-Aldopentofuranosyl-N′-[p-(isoamyloxy)phenyl]-thiourea derivatives:: Potential anti-TB therapeutic agents
Liav, Avraham
Angala, Shiva K.
Brennan, Patrick J.
Jackson, Mary
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (08) : 2649 - 2651
[9] ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates
Morlock, GP
Metchock, B
Sikes, D
Crawford, JT
Cooksey, RC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) : 3799 - 3805
[10] Muller B, INT J TUBERC LUNG DI, V15, P344

← 1 2 →